We also demonstrated that the PGC1α-specific agonist ZLN005 combined with the hypoglycemic drug rosiglitazone synergistically treated CRC by inhibiting tumor growth by downregulating the Warburg effect. Here, PPARGC1A is linked to neoplasm.